The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B

  • Yang, Hyeon-Woong (Department of Internal Medicine, Eulji University School of Medicine) ;
  • Lee, Byung-Seok (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Lee, Tae-Hee (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Lee, Heon-Young (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Nam, Kwan-Woo (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Kang, Young-Woo (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Chae, Hee-Bok (Department of Internal Medicine, Chungbuk National University College of Medicine) ;
  • Kim, Seok-Hyun (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Kim, Seok-Bae (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Lee, Hyang-Ie (Department of Internal Medicine, Eulji University School of Medicine) ;
  • Kim, An-Na (Department of Internal Medicine, Eulji University School of Medicine) ;
  • Song, Il-Han (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Lee, Sae-Hwan (Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Kim, Hong-Su (Department of Internal Medicine, Soonchunhyang University College of Medicine)
  • Received : 2009.12.31
  • Accepted : 2010.09.14
  • Published : 2010.12.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naive patients with CHB living in Daejeon and Chungcheong Province, South Korea. Methods: One hundred five adults with CHB were administered 30 mg of clevudine per day for an average of 51 weeks. We evaluated viral markers and liver biochemistry retrospectively every 3 months. Results: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatitis B virus (HBV) DNA before the treatment were $184{\pm}188$ IU/L, $150{\pm}138$ IU/L, and $7.1{\pm}1.2$ log copies/mL, respectively. Undetectable rates (< 60 IU/mL) of DNA were 36.2%, 68.9%, 83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks, respectively. Seroconversion rates were 9.1%, 13.6%, 24.6%, 26.5%, and 26.1% and ALT normalization rates were 64.5%, 78.1%, 87.9%, 90.0% at 12, 24, 36, and 48 weeks, respectively. Six patients (5.7%) had a viral breakthrough. Conclusions: Clevudine is a useful drug in the initial treatment of patients with CHB, with a potent antiviral effect and low incidence of viral breakthrough.

Keywords

References

  1. Lee KS, Byun KS, Chung YH, et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology 2007;50:296-302. https://doi.org/10.1159/000105442
  2. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005;25 Suppl 1:9-19. https://doi.org/10.1055/s-2005-915645
  3. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722. https://doi.org/10.1053/j.gastro.2003.09.033
  4. Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther 2006;28:184-203. https://doi.org/10.1016/j.clinthera.2006.02.012
  5. Koh KH, Kang CJ, Kim DH, et al. Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B. Korean J Gastroenterol 2008;52:325-328.
  6. Liu SH, Grove KL, Cheng YC. Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother 1998;42:833-839.
  7. Marcellin P, Mommeja-Marin H, Sacks SL, et al. A phase II doseescalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-148.
  8. Lee HS, Chung YH, Lee K, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2006;43:982-988. https://doi.org/10.1002/hep.21166
  9. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-1178. https://doi.org/10.1002/hep.21629
  10. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-1048. https://doi.org/10.1002/hep.21800
  11. Lim SG, Leung N, Hann HW, et al. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther 2008;27:1282-1292. https://doi.org/10.1111/j.1365-2036.2008.03686.x
  12. Niu C, Murakami E, Furman PA. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antivir Ther 2008;13:263-269.
  13. Kim MH, Kim KA, Lee JS, et al. Efficacy of 48-week clevudine therapy for chronic hepatitis B. Korean J Hepatol 2009;15:331-337. https://doi.org/10.3350/kjhep.2009.15.3.331
  14. Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001;4:118-128. https://doi.org/10.1054/drup.2001.0190
  15. Ferenci P. Treatment of chronic viral hepatitis. Best Pract Res Clin Gastroenterol 2004;18 Suppl:113-120. https://doi.org/10.1016/j.bpg.2004.06.020

Cited by

  1. Drugs in Development for the Treatment of Chronic Hepatitis B vol.11, pp.2, 2010, https://doi.org/10.1007/s11901-012-0131-9
  2. Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Naïve Patients with Chronic Hepatitis B vol.6, pp.4, 2010, https://doi.org/10.5009/gnl.2012.6.4.486
  3. Efficacy of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-induced Myopathy vol.61, pp.1, 2010, https://doi.org/10.4166/kjg.2013.61.1.30